Wolverine Trading, LLC Corbus Pharmaceuticals Holdings, Inc. Call Options Transaction History

Wolverine Trading, LLC

$103 Billion
Q4 2024

Call Options

17 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$0.21 - $0.53 $4,137 - $10,441	-19,700 Reduced 42.0%	27,200 $7,000
Q1 2022 May 16, 2022	BUY	$0.32 - $0.67 $7,584 - $15,879	23,700 Added 102.16%	46,900 $24,000
Q4 2021 Feb 14, 2022	SELL	$0.6 - $1.11 $5,880 - $10,878	-9,800 Reduced 29.7%	23,200 $14,000
Q3 2021 Nov 12, 2021	SELL	$1.01 - $1.82 $4,545 - $8,190	-4,500 Reduced 12.0%	33,000 $33,000
Q2 2021 Aug 06, 2021	SELL	$1.39 - $2.21 $36,974 - $58,786	-26,600 Reduced 41.5%	37,500 $69,000
Q1 2021 May 14, 2021	SELL	$1.27 - $3.42 $1,397 - $3,762	-1,100 Reduced 1.69%	64,100 $119,000
Q4 2020 Feb 12, 2021	SELL	$0.94 - $1.89 $49,726 - $99,981	-52,900 Reduced 44.79%	65,200 $83,000
Q3 2020 Nov 13, 2020	BUY	$1.5 - $9.38 $133,050 - $832,006	88,700 Added 301.7%	118,100 $233,000
Q2 2020 Aug 13, 2020	BUY	$4.79 - $8.39 $22,513 - $39,433	4,700 Added 19.03%	29,400 $233,000
Q1 2020 May 11, 2020	BUY	$3.44 - $7.21 $39,904 - $83,636	11,600 Added 88.55%	24,700 $136,000
Q4 2019 Feb 12, 2020	SELL	$4.29 - $5.64 $132,990 - $174,840	-31,000 Reduced 70.29%	13,100 $70,000
Q3 2019 Nov 14, 2019	BUY	$4.87 - $7.08 $15,097 - $21,948	3,100 Added 7.56%	44,100 $221,000
Q2 2019 Aug 20, 2019	SELL	$6.6 - $7.8 $27,720 - $32,760	-4,200 Reduced 9.29%	41,000 $284,000
Q1 2019 May 15, 2019	BUY	$5.76 - $8.95 $175,104 - $272,080	30,400 Added 205.41%	45,200 $314,000
Q4 2018 Feb 14, 2019	SELL	$5.26 - $7.97 $84,686 - $128,317	-16,100 Reduced 52.1%	14,800 $87,000
Q3 2018 Nov 14, 2018	SELL	$4.65 - $7.95 $31,155 - $53,265	-6,700 Reduced 17.82%	30,900 $233,000
Q1 2018 May 15, 2018	BUY	$5.6 - $9.25 $210,560 - $347,800	37,600 New	37,600 $229,000

About Corbus Pharmaceuticals Holdings, Inc.

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $853M
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

More about CRBP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account